Introduction
============

Cholangiocarcinoma (CCA) is the second most common primary hepatobiliary tumor worldwide; its overall incidence and mortality appear to be increasing \[[@goy049-B1]\]. Pre-operative biliary drainage (PBD) is routinely performed in patients with extra-hepatic CCA. This is based on the fact that, in several experimental studies and retrospective case series, PBD reduced morbidity and mortality after surgery \[[@goy049-B5]\]. However, subsequently published meta-analyses of randomized trials showed that the overall complication rate was higher in patients undergoing PBD for jaundice secondary to obstructive tumors than in patients who proceeded directly to surgery \[[@goy049-B8], [@goy049-B9]\]. PBD has been found to be associated with bacteriobilia or fungal colonization, higher rates of post-operative sepsis, wound infection, longer hospital stay and increased cost \[[@goy049-B10]\]. Although most of these data relate to tumors other than CCA, the British Society of Gastroenterology to formulate guidelines stated that PBD is controversial and its routine use should not be recommended \[[@goy049-B5], [@goy049-B14]\]. Currently, the only potential curative therapy for CCA is surgical resection; for highly selective patients in certain transplant centers, liver transplantation is offered as an alternative treatment.

Despite the lack of a beneficial effect for PBD in CCA patients \[[@goy049-B10]\], most patients with jaundice in many centers undergo pre-operative drainage. PBD is usually performed via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous trans-hepatic biliary drainage. Up to now, the impact of PBD on survival in patients with CCA is uncertain. In this study, we analysed the Surveillance, Epidemiology and End Results (SEER) database linked to Medicare claims and aimed to evaluate the impact of PBD on long-term overall survival in patients with CCA.

Methods
=======

Data source
-----------

The data in the present study were obtained from the SEER-Medicare database that links cancer-registry data to Medicare enrollment and claims files. Information on patient demographics, tumor site, morphology, stage, treatment and follow-up was obtained by SEER registries from hospital and outpatient records. The quality and completeness of the data were ascertained in even-numbered calendar years. Medicare is the primary health insurer for 97% of the US population aged 65 years and older. Approximately 99% of Medicare beneficiaries receive Part A benefits (Hospital Insurance) and approximately 95% subscribe to Part B benefits (Medical Insurance), covering outpatient hospital care and physicians' visits. Data on Medicare claims are available for Medicare Parts A and B. These files contain dates of service, International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) diagnosis codes and Current Procedural Terminology (CPT, Version 4) codes for all billed claims.

The SEER database consists of de-identified data with no risk of loss of confidentiality. The present study was approved by the Florida Hospital Institutional Review Board (Florida, USA).

Study population
----------------

All persons aged ≥65 years who were diagnosed with histologically confirmed extra-hepatic CCA between 2001 and 2011 were identified. The histologic definition of CCA was based on the World Health Organization's classification \[[@goy049-B4]\]. The SEER registry identifies CCA using the International Classification of Disease for Oncology, 3rd edition (ICD-O3) during the study period. We further stratified our analyses by anatomical subtypes of extra-hepatic CCA (proximal vs distal CCA) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Available data that were abstracted include patient demographics (e.g. age, sex, race), tumor data (histology, grade), SEER stage of disease, use of radiotherapy and details of surgical therapy. Only persons enrolled in Medicare Parts A and B for at least 1 year before the diagnosis of CCA were eligible for inclusion to insure adequate time for prior diagnoses to be recorded. The patients diagnosed at autopsy or at the time of death with CCA were excluded. The Deyo adaptation of the Charlson comorbidity index (CCI) was used to assess comorbidities in the study population \[[@goy049-B15]\]. All files during the period of 3 months before and 3 months after the date of pathological diagnosis were examined for procedure codes for ERCP and/or percutaneous trans-hepatic biliary drainage ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

All patients included in the present study underwent curative-intent surgery, chemotherapy and radiotherapy based on the codes from SEER database and Medicare claims. Information on post-procedural adverse events (pancreatitis, hemorrhage and perforation within 30 days) after ERCP procedure or percutaneous trans-hepatic biliary drainage and before surgery was recorded. Post-ERCP pancreatitis requires the ICD-9 code of 997.4 (complication of gastrointestinal procedure) along with the pancreatitis code (577.0). Bleeding after ERCP was identified by specific ICD-9 codes used to define post-ERCP hemorrhage (998.11, 909.3 and V58.89). Perforation after ERCP was identified by using ICD-9 code 569.83. All Medicare claims with procedure codes or revenue center codes were obtained from Medicare Provider Analysis and Review, outpatient claims files and physician/supplier files. To minimize the possibility of erroneously including cancer metastases to the bile duct, persons with prior diagnoses of gastrointestinal, lung, breast and prostate cancers were excluded.

Statistical analyses
--------------------

The study population was divided into two groups: patients who received biliary drainage (the PBD cohort) and patients who did not receive any biliary drainage (the non-PBD cohort). Baseline characteristics were compared between the groups with χ^2^ test or independent *t*-test, as appropriate. A *P*-value less than 0.05 was considered statistically significant. We studied long-term outcomes of all patients with extra-hepatic CCA, and then analysed the data of subgroups of patients who underwent curative surgical resection to explore the impact of PBD on overall survival. Overall survival time was calculated from the date of diagnosis to the date of death or the date of the last follow-up. Kaplan--Meier estimates were used to calculate overall survival. The Cox proportional hazard model was used for multivariable analyses to identify factors associated with the overall survival after adjustment for all possible factors, such as age, sex, race, stage of cancer, CCI, tumor location, histological pathology, tumor grade, SEER regions (Northeast, Midwest, South and West, as defined by the United States Census Bureau), year of diagnosis, any biliary drainage performed, location of CCA (distal vs proximal), chemotherapy and radiotherapy; the corresponding adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were reported. All data were analysed using STATA Statistics software (V.14; STATA Corporation, College Station, TX, USA).

Results
=======

Demographics of patients
------------------------

A total of 3862 patients with extra-hepatic CCA were identified from the database, including 1071 patients (27.7%) in the PBD group (ERCP and/or percutaneous trans-hepatic biliary drainage) and 2791 patients (72.3%) in the non-PBD group. Of 3862 patients with extra-hepatic CCA, 433 (11.2%) underwent curative-intent surgical resection. Among the 433 patients, 119 (27.5%) underwent ERCP, including 23 patients who also underwent concomitant percutaneous trans-hepatic biliary drainage; 7 (1.6%) underwent percutaneous trans-hepatic biliary drainage only; and the remaining 307 (70.9%) did not undergo ERCP or percutaneous trans-hepatic biliary drainage.

The baseline demographic and clinical characteristics of patients and cancer-related variables in 433 patients in the surgical cohort and 3429 patients in the non-surgical cohort are shown in [Tables 1](#goy049-T1){ref-type="table"} and [2](#goy049-T2){ref-type="table"}, respectively. Patients in the PBD cohort had more comorbidities than those in the non-PBD cohort. The results showed no propensity to undergo PBD based on the comparison of age, sex, race, location of CCA (proximal vs distal) or grade of tumor between the patients in the surgical cohort who underwent biliary drainage or did not ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). [Table 2](#goy049-T2){ref-type="table"} highlights the demographic and clinical variables in patients who underwent biliary drainage and those who did not in the non-surgical cohort (*n* = 3429). Patients in the PBD cohort had more comorbidities than those in the non-PBD cohort. [Supplementary Table 4](#sup1){ref-type="supplementary-material"} highlights the demographic and clinical variables in CCA patients with distal and proximal/hilar CCA.

###### 

Comparison of characteristics between the PBD group and the non-PBD group in 433 patients with cholangiocarcinoma who underwent surgery between 2001 and 2011

  Characteristic                                                         **PBD (*n*** **=** **126)**   **Non-PBD (*n*** **=** **307)**   *P*-value
  ---------------------------------------------------------------------- ----------------------------- --------------------------------- -----------
  Mean age at diagnosis, years (SD)[^a^](#tblfn1){ref-type="table-fn"}   72.9 (5.4)                    73.6 (5.3)                        0.190
  Sex                                                                                                                                    0.470
   Female                                                                60 (47.6)                     158 (51.5)                        
   Male                                                                  66 (52.4)                     149 (48.5)                        
  Race                                                                                                                                   0.870
   Caucasian                                                             101 (80.2)                    244 (79.5)                        
   Other                                                                 25 (19.8)                     63 (20.5)                         
  Diagnosis year                                                                                                                         0.460
   2001--05                                                              52 (41.3)                     115 (37.5)                        
   2006--11                                                              74 (58.7)                     192 (62.5)                        
  Region                                                                                                                                 0.750
   Northeast                                                             4 (3.2)                       15 (4.9)                          
   Midwest                                                               12 (9.5)                      23 (7.5)                          
   South                                                                 52 (41.3)                     113 (36.8)                        
   West                                                                  53 (42.1)                     143 (46.6)                        
   Unknown                                                               5 (4.0)                       13 (4.2)                          
  Charlson comorbidity index                                                                                                             0.005
   0                                                                     34 (27)                       126 (41)                          
   1                                                                     20 (15.9)                     59 (19.2)                         
   2                                                                     23 (18.3)                     30 (9.8)                          
   ≥3                                                                    49 (38.9)                     92 (30.0)                         
  Location of CCA                                                                                                                        0.100
   Distal                                                                122 (96.8)                    304 (99.0)                        
   Proximal                                                              4 (3.2)                       3 (1.0)                           
  SEER stage                                                                                                                             0.003
   Localized                                                             55 (43.7)                     191 (62.2)                        
   Regional                                                              49 (38.9)                     71 (23.1)                         
   Distant                                                               15 (11.9)                     29 (9.5)                          
   Unstaged                                                              7 (5.6)                       16 (5.2)                          
  Grade                                                                                                                                  0.910
   Well differentiated                                                   13 (10.3)                     26 (8.5)                          
   Moderately differentiated                                             41 (32.5)                     103 (33.6)                        
   Poorly differentiated                                                 30 (23.8)                     79 (25.7)                         
   Unknown or undifferentiated                                           42 (33.3)                     99 (32.3)                         
  Chemotherapy                                                                                                                           0.190
   No                                                                    98 (77.8)                     255 (83.1)                        
   Yes                                                                   28 (22.2)                     52 (16.9)                         
  Radiotherapy                                                                                                                           \<0.001
   No                                                                    101 (80.2)                    284 (92.5)                        
   Yes                                                                   25 (19.8)                     23 (7.5)                          
  Post-surgery radiotherapy                                                                                                              0.140
   No                                                                    108 (85.7)                    278 (90.6)                        
   Yes                                                                   18 (14.3)                     29 (9.5)                          
  Median overall survival, months (95% CI)a                              14 (10--21)                   31 (26--39)                       \<0.001

^a^Except these, other values are presented as the number of patients followed by percentage in parentheses.

PBD, pre-operative biliary drainage; SD, standard deviation; CCA, cholangiocarcinoma; SEER, Surveillance, Epidemiology, and End Results Program; CI, confidence interval.

###### 

Comparison of characteristics between the biliary drainage group and the non-biliary drainage group in 3429 patients with cholangiocarcinoma who did not undergo surgery between 2001 and 2011

  Characteristic                             Biliary drainage (*n* = 945)   Non-biliary drainage (*n* = 2484)   *P*-value
  ------------------------------------------ ------------------------------ ----------------------------------- -----------
  Mean age at diagnosis, years (SD)          77.7 (7.3)                     77.8 (7.5)                          0.570
  Sex                                                                                                           0.140
   Female                                    527 (55.8)                     1315 (52.9)                         
   Male                                      418 (44.2)                     1169 (47.1)                         
  Race                                                                                                          0.850
   Caucasian                                 228 (24.1)                     607 (24.4)                          
   Other                                     717 (75.9)                     1877 (75.6)                         
  Diagnosis year                                                                                                \<0.001
   2001--05                                  467 (30.8)                     1051 (69.2)                         
   2006--11                                  478 (25.0)                     1433 (75.0)                         
  Region                                                                                                        0.001
   Northeast                                 39 (4.1)                       133 (5.4)                           
   Midwest                                   83 (8.8)                       235 (9.5)                           
   South                                     295 (31.2)                     598 (24.1)                          
   West                                      486 (51.4)                     1380 (55.6)                         
   Unknown                                   42 (4.4)                       138 (5.6)                           
  Charlson comorbidity index                                                                                    \<0.001
   0                                         252 (26.7)                     1095 (44.1)                         
   1                                         216 (22.9)                     431 (17.4)                          
   2                                         137 (14.5)                     237 (9.5)                           
   ≥3                                        340 (36.0)                     721 (29.0)                          
  Location of CCA                                                                                               \<0.001
   Distal                                    836 (88.5)                     2448 (98.6)                         
   Proximal                                  109 (11.5)                     36 (1.5)                            
  SEER stage                                                                                                    0.002
   Localized                                 229 (24.2)                     528 (21.3)                          
   Regional                                  214 (22.7)                     466 (18.8)                          
   Distant                                   230 (24.3)                     639 (25.7)                          
   Unstaged                                  272 (28.8)                     851 (34.3)                          
  Grade                                                                                                         0.010
   Well differentiated                       22 (2.3)                       67 (2.7)                            
   Moderately differentiated                 77 (8.2)                       223 (9)                             
   Poorly differentiated                     91 (9.6)                       331 (13.3)                          
   Unknown or undifferentiated               755 (79.9)                     1863 (75)                           
  Chemotherapy                                                                                                  0.008
   No                                        748 (79.2)                     2063 (83.0)                         
   Yes                                       197 (20.9)                     421 (17.0)                          
  Radiotherapy                                                                                                  \<0.001
   No                                        824 (87.2)                     2379 (95.8)                         
   Yes                                       121 (12.8)                     105 (4.2)                           
  Median overall survival, months (95% CI)   4.0 (4.0--5.0)                 5.0 (4.0--5.0)                      0.004

SD, standard deviation; CCA, cholangiocarcinoma; SEER, Surveillance, Epidemiology, and End Results Program; CI, confidence interval.

Outcomes of patients undergoing surgery
---------------------------------------

During a median follow-up duration of 5 months (range, 1--60 months), 433 (11.2%) patients underwent curative-intent surgical resection. The median follow-up duration for the surgical cohort was 26 months (range, 1--60 months). The median overall survival time was 14 months (95% CI, 10--21 months) in the PBD cohort (*n* = 126) vs 31 months (95% CI, 26--39 months) in the non-PBD (*n* = 307) cohort (*P* **\<** 0.001) ([Figure 1](#goy049-F1){ref-type="fig"}). The median overall survival was significantly shorter in patients who underwent drainage (ERCP and/or percutaneous trans-hepatic biliary drainage, irrespective of drainage) than in patients who proceeded directly to surgery (*P* = 0.003) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). In the multivariable Cox regression model, among 433 patients who underwent curative-intent surgical resection, after adjusting age, race, sex, tumor location, stage, grade, SEER site, CCI, radiotherapy and chemotherapy, PBD was significantly associated with shortened survival time (HR, 2.35; 95% CI, 1.34--4.10; *P* = 0.003). Other variables associated with shortened survival time included SEER stage, CCI and poorly differentiated tumor. The location of CCA (proximal vs distal) was not significantly associated with overall survival (HR, 1.45; 95% CI, 0.60--3.50; *P* = 0.400) ([Table 3](#goy049-T3){ref-type="table"}).

![Comparison of 5-year overall survival curves in the PBD cohort (*n* = 126) and the no-PBD cohort (*n* = 307) among patients with cholangiocarcinoma who underwent curative surgery between 2001 and 2011](goy049f1){#goy049-F1}

###### 

Multivariable Cox regression analysis of factors associated with overall survival in 433 patients diagnosed with cholangiocarcinoma who underwent curative surgery

  Variable                                                 HR              95% CI        *P*-value
  -------------------------------------------------------- --------------- ------------- -----------
  Treatment before surgery                                                               
  No ERCP or percutaneous trans-hepatic biliary drainage   1 (Reference)                 
  Percutaneous trans-hepatic biliary drainage alone        0.83            0.29--2.33    0.730
  ERCP alone                                               1.26            0.91--1.75    0.170
  ERCP and percutaneous trans-hepatic biliary drainage     2.35            1.34--4.10    0.003
  Age at diagnosis, years                                  0.99            0.97--1.03    0.950
  Male vs female                                           1.13            0.87--1.47    0.370
  Caucasian vs others                                      0.78            0.57--1.08    0.140
  SEER stage                                                                             
   Localized                                               1 (Reference)                 
   Regional                                                1.95            1.43--2.66    \<0.001
   Distant                                                 5.07            3.36--7.64    \<0.001
   Unstaged                                                1.16            0.63--2.14    0.630
  Cancer type of cholangiocarcinoma                                                      
   Distal                                                  1 (Reference)                 
   Proximal                                                1.45            0.60--3.50    0.400
  Charlson comorbidity index                                                             
   0                                                       1 (Reference)                 
   1                                                       1.10            0.75--1.63    0.630
   2                                                       1.51            1.002--2.27   0.050
   ≥3                                                      1.53            1.11--2.10    0.010
  Post-procedure adverse event                                                           
   Hemorrhage                                              1.09            0.51--2.31    0.830
   Acute pancreatitis                                      1.49            0.85--2.63    0.160
   Perforation                                             4.21            1.70--10.40   0.002
   Acute cholecystitis                                     1.75            0.88--3.47    0.110
  Grade                                                                                  
   Well differentiated                                     1 (Reference)                 
   Moderately differentiated                               0.91            0.52--1.59    0.740
   Poorly differentiated                                   1.76            1.01--3.06    0.050
   Unknown or undifferentiated                             1.26            0.73--2.16    0.410
  Region                                                                                 
   Northeast                                               1 (Reference)                 
   Midwest                                                 0.48            0.24--0.99    0.050
   South                                                   0.41            0.22--0.76    0.004
   West                                                    0.55            0.30--0.99    0.050
   Unknown                                                 0.69            0.32--1.49    0.360
  Year at diagnosis                                                                      
   2001--05                                                1 (Reference)                 
   2006--11                                                0.93            0.71--1.23    0.620
  Chemotherapy (yes vs no)                                 0.97            0.69--1.35    0.840
  Radiation therapy (yes vs no)                            0.91            0.61--1.39    0.690

ERCP, endoscopic retrograde cholangiopancreatography; SEER, Surveillance, Epidemiology, and End Results Program.

Outcomes of patients undergoing no surgical treatment
-----------------------------------------------------

In the multivariable Cox regression model in 3429 patients who did not undergo surgery, after adjusting for age, race, sex, tumor location, stage, grade, SEER site, CCI, radiotherapy and chemotherapy, biliary drainage (no matter which type) was significantly associated with shortened survival time: ERCP alone without percutaneous trans-hepatic biliary drainage (HR, 1.18; 95% CI, 1.06--1.31; *P* = 0.002), ERCP and percutaneous trans-hepatic biliary drainage (HR, 1.27; 95% CI, 1.08--1.49; *P* = 0.003) and percutaneous trans-hepatic biliary drainage alone without ERCP (HR, 1.53; 95% CI, 1.20--1.96; *P* = 0.001). Other variables significantly associated with shortened survival time included SEER stage, CCI and poorly differentiated or undifferentiated tumor. Chemotherapy and radiotherapy were significantly associated with prolonged overall survival ([Table 4](#goy049-T4){ref-type="table"}). The median overall survival was not significantly different between patients who underwent drainage (ERCP and/or percutaneous trans-hepatic biliary drainage) and patients who did not undergo biliary drainage ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}).

###### 

Multivariable Cox regression analysis of factors associated with long-term survival of 3429 patients diagnosed with cholangiocarcinoma who did not undergo surgery between 2001 and 2011

  Variable                                                 HR              95% CI       *P*-value
  -------------------------------------------------------- --------------- ------------ -----------
  Treatment before surgery                                                              
  No ERCP or percutaneous trans-hepatic biliary drainage   1 (Reference)                
  Percutaneous trans-hepatic biliary drainage alone        1.53            1.20--1.96   0.001
  ERCP alone                                               1.18            1.06--1.31   0.002
  ERCP and percutaneous trans-hepatic biliary drainage     1.27            1.08--1.49   0.003
  Age at diagnosis, years                                  1.01            1.01--1.02   \<0.001
  Male vs female                                           0.98            0.91--1.06   0.610
  Caucasian vs others                                      1.2             1.09--1.32   \<0.001
  SEER stage                                                                            
   Localized                                               1 (Reference)                
   Regional                                                1.21            1.08--1.37   0.002
   Distant                                                 1.48            1.32--1.66   0.003
   Unstaged                                                1.29            1.16--1.44   0.003
  Cancer type                                                                           
   Distal                                                  1 (Reference)                
   Proximal                                                0.89            0.74--1.08   0.240
  Charlson comorbidity index                                                            
   0                                                       1 (Reference)                
   1                                                       1.05            0.94--1.17   0.380
   2                                                       1.04            0.91--1.18   0.610
   ≥3                                                      1.14            1.03--1.25   0.008
  Post-procedure adverse event                                                          
   Hemorrhage                                              0.97            0.69--1.37   0.860
   Acute pancreatitis                                      0.92            0.76--1.1    0.350
   Perforation                                             1.17            0.67--2.03   0.580
   Post-operative infection                                1.44            0.81--2.55   0.220
   Acute cholecystitis                                     0.79            0.6--1.03    0.080
  Grade                                                                                 
   Well differentiated                                     1 (Reference)                
   Moderately differentiated                               1.24            0.94--1.62   0.120
   Poorly differentiated                                   1.42            1.09--1.85   0.010
   Unknown or undifferentiated                             1.24            0.97--1.58   0.090
  Region                                                                                
   Northeast                                               1 (Reference)                
   Midwest                                                 0.87            0.7--1.08    0.210
   South                                                   0.85            0.71--1.03   0.090
   West                                                    0.94            0.79--1.13   0.510
   Unknown                                                 1.06            0.84--1.34   0.630
  Year at diagnosis                                                                     
   2001--05                                                1 (Reference)                
   2006--11                                                1.13            1.04--1.22   0.003
  Chemotherapy (yes vs no)                                 0.74            0.66--0.82   0.005
  Radiotherapy (yes vs no)                                 0.81            0.69--0.94   0.007

ERCP, endoscopic retrograde cholangiopancreatography; SEER, Surveillance, Epidemiology, and End Results Program.

Discussion
==========

ERCP and/or percutaneous trans-hepatic biliary drainage is frequently performed for biliary drainage in patients with CCA. In this study, we found that PBD was associated with shortened overall survival time and therefore we thought that PBD must be avoided if possible in patients with potentially resectable CCA. Also, biliary drainage was associated with decreased overall survival in non-surgical patients with CCA.

There is conflicting evidence on the impact of PBD on long-term survival in patients with malignant obstructive jaundice. Endoscopic PBD, placing a plastic stent for cancer of the pancreatic head, was associated with increased rate of complications compared with direct surgery treatment in patients with cancer of the head of the pancreas; however, the short-term survival time did not differ between the two groups \[[@goy049-B16]\]. In studies of patients with pancreatic and ampullary carcinoma, the overall survival was not significantly different between patients who underwent PBD and those who did not \[[@goy049-B17], [@goy049-B18]\]. In a study that investigated the impact of PBD in patients with pancreatic and ampullary cancers, there were lower rates of resection and R0 resection in the biliary drainage group versus the early surgery cohort \[[@goy049-B19]\]. Although the overall survival did not reach statistical significance, the results were clinically relevant. A recent study of 141 patients with hilar CCA studied the impact of PBD on overall survival \[[@goy049-B20]\]. It included only patients who underwent PBD with the percutaneous technique (*n* = 67) or ERCP (*n* = 74) and did not enroll patients who directly went to surgery \[[@goy049-B20]\]. Percutaneous trans-hepatic biliary drainage was independently associated with poor survival and patients developed peritoneal seeding more frequently in comparison to those who underwent ERCP. Also, percutaneous trans-hepatic biliary drainage was the only independent factor predictive of peritoneal seeding \[[@goy049-B20]\]. In our study, we observed that PBD was associated with shortened survival time in patients with resectable CCA. We could not differentiate the impact of ERCP and percutaneous trans-hepatic biliary drainage independently because of small numbers of patients in the percutaneous trans-hepatic biliary drainage group in the surgical cohort.

Post-operative complications have been recognized as a prognostic factor for survival in patients with pancreatic cancer \[[@goy049-B21], [@goy049-B22]\]; however, similar evidence for CCA is lacking. The reason for shortened survival in patients with CCA could be explained based on three hypotheses. First, biliary drainage could result in systemic inflammatory response syndrome such as cholangitis or pancreatitis. The presence of viable tumor cells, especially those at the anastomotic sites, combined with a systemic inflammatory response syndrome leads to the release of pro-inflammatory cytokines and growth factors. The pro-inflammatory state with immune surveillance suppression may stimulate the growth of residual tumor cells resulting in lower long-term survival \[[@goy049-B23], [@goy049-B24]\]. While the occurrence of adverse events related to ERCP was not directly associated with shortened survival, the development of systemic inflammatory response syndrome could be indolent and not clinically detected. Second, biliary drainage (in particular percutaneous trans-hepatic biliary drainage) may result in bile spillage, which may contain exfoliated tumor cells that could result in peritoneal recurrence. Several reports have demonstrated that percutaneous drainage may increase the risk of catheter tract recurrence or peritoneal dissemination and therefore results in shortened survival \[[@goy049-B20], [@goy049-B25]\]. However, because of the limited number of patients who underwent percutaneous trans-hepatic biliary drainage in our surgical cohort, we could not independently study its effect. Third, patients who underwent biliary drainage were a sicker subpopulation of patients with CCA and thus had shortened survival compared with patients who did not undergo biliary drainage.

It is important to understand the implication of biliary drainage in CCA. Although PBD was associated with shortened survival time, only 11.2% (433/3862) of patients were eligible for surgical resection in our cohort. The remaining patients who were not eligible for undergoing surgical resection needed biliary drainage. In clinical practice, almost 90% of CCA patients are unresectable/borderline resectable and will continue to need biliary drainage to palliate jaundice. Even though we observed that biliary drainage is associated with shortened survival time in patients who would not undergo surgery, the quality of life of patients who undergo drainage may be better. The other caveat is that, among the 3862 patients with CCA, only 1071 (27.7%) patients underwent biliary drainage. In fact, among 433 patients who underwent surgery, 307 (70.9%) did not receive biliary drainage. In addition, our results are applicable more to patients with distal CCA, as most patients in our cohort had distal CCA.

There are several limitations in our study. First, the information on surgical margins was not available and neither were data on types of stents placed during ERCP or the caliber of percutaneous drainage catheters. Second, our findings are applicable only to patients older than 65 years. However, most CCA occur in older patients except in the setting of primary sclerosing cholangitis. Third, this was a non-randomized study and therefore whether the patients underwent ERCP and/or percutaneous trans-hepatic biliary drainage or directly underwent surgery is difficult to decided by the practice pattern of the institution and available expertise. Lastly, patients in the PBD cohort had more comorbidity than those in the non-PBD cohort. It is possible that the poor clinical outcomes could be related to their underlying comorbidity. However, we had adjusted for comorbidities in the multivariable analysis and the comorbidities did not impact overall survival. The SEER database does not provide bilirubin levels---a critical missing variable to compare the degree of biliary obstruction between both cohorts. Finally, we could not study the independent impact of ERCP alone or percutaneous trans-hepatic biliary drainage alone on outcomes in surgical patients because of the limited number of patients.

Despite these limitations, our study had several strengths. First, our study included a large number of patients, which was powered to find relatively small differences in survival. The SEER-Medicare registry contains population-based data, and therefore the results are more generalizable to the US population than data from tertiary cancer centers. Finally, we defined curative cancer-directed surgery as it is defined in the SEER database that includes a range of procedures from hepatectomy to pancreaticoduodenectomy and therefore our analysis reflects the full range of practice patterns in the treatment of CCA in the USA, and not just the results of specialized centers that employ specific surgical approaches.

In conclusion, PBD may be associated with shortened survival and may need to be avoided if possible in patients with resectable CCA. Our study also suggests that the use of biliary drainage may negatively impact outcomes even in non-surgical patients with CCA. A randomized trial studying the impact of biliary drainage on overall outcomes is urgently needed to confirm these observations.
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